Jeffrey S. Hochman

Partner

New York
Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, NY 10019-6099
T 212 728 8592
F 212 728 9592
jhochmanwillkie.com

Jeffrey S. Hochman is a partner in the Corporate and Financial Services Department. He focuses on mergers and acquisitions of both public and private companies, public offerings, private equity transactions and general corporate and securities law. He regularly advises boards of directors and executives regarding corporate governance issues and other sensitive matters.

Over the past several years, Jeffrey has worked closely with a broad range of companies, including pharmaceutical, insurance and technology companies. He advises issuers on ongoing SEC disclosure and other corporate matters, while also representing underwriters in connection with various securities offerings. Jeffrey has also worked on a number of "going private" transactions and special committee assignments, as well as other securities and M&A transactions.

+ Continue Reading

Highlights

Jeffrey S. Hochman is a partner in the Corporate and Financial Services Department. He focuses on mergers and acquisitions of both public and private companies, public offerings, private equity transactions and general corporate and securities law. He regularly advises boards of directors and executives regarding corporate governance issues and other sensitive matters.

Selected Significant Matters

Recent significant transactions include representing:

  • Teva Pharmaceutical Industries Ltd. in its series of three multi-tranche, multi-market offerings of senior notes aggregating $20.4 billion to finance its pending acquisition of Actavis Generics, the worldwide generic pharmaceutical business of Allergan plc.
  • Teva Pharmaceutical in its $6.75 billion aggregate stock offerings supporting its pending acquisition of Actavis Generics
  • Special Committee of the Board of Directors of WuXi PharmaTech Inc. in its $3.3 billion management-led leveraged buyout
  • HealthEquity (HQY) in its initial public offering and follow-on offerings
  • Teva Pharmaceutical Industries Ltd. in its €2 billion multi-tranche Eurobond offering
  • Teva Pharmaceutical Industries Ltd. in its $1.3 billion debt tender offer for five series of senior notes
  • New Breed Holding Company in its $615 million acquisition by XPO Logistics, Inc.
  • Peter J. Solomon Company as financial adviser to R.G. Barry Corporation in R.G. Barry’s acquisition by Mill Road Capital
  • Teva Pharmaceutical Industries Limited in its $2 billion offering of senior notes
  • Doublemousse B.V. and Moussetrap as the selling stockholders in the $588 million secondary offering of Ulta Beauty common stock
  • Teva Pharmaceutical Industries Limited in its debut €1 billion and CHF 450 million Regulation S offerings of senior notes
  • AboveNet Inc.’s Board of Directors in connection with AboveNet’s approximately $2.2 billion agreement to be acquired by Zayo Group LLC
  • W. R. Berkley Corporation in connection with various public offerings of common stock, senior notes and trust preferred securities, including its recent $290 million offering of subordinated debentures, $110 million offering of subordinated debentures, $350 million offering of senior notes and $350 million offering of subordinated debentures
  • Teva Pharmaceutical Industries Limited in its $5 billion offering of senior notes – the largest securities offering by an Israeli company
  • Allied World Assurance Company Holdings, AG in connection with Transatlantic Holdings, Inc.
  • The special committee of M&F Worldwide Corp. in connection with its $483 million merger agreement with MacAndrews & Forbes Holdings Inc.
  • Teva Pharmaceutical Industries Limited in its consumer health care joint venture with The Procter & Gamble Company
  • Teva Pharmaceutical Industries Limited in its $750 million offering of senior notes
  • Teva Pharmaceutical Industries Limited in its $2.5 billion offering of senior notes
  • The underwriters in PartnerRe Ltd’s $500 million offering of senior notes
  • RenaisanceRe Holdings Ltd. in its investment in Essent Group Ltd., the first private mortgage insurance company in the United States since the start of the current financial crisis
  • RenaisanceRe Holdings Ltd. in the creation of a Timicuan Reinsurance II Ltd., a new Bermuda reinsurance “sidecar” company established to provide additional reinsurance capacity for the Florida homeowners market
  • The underwriters in The Allstate Corporation’s $1 billion offering of senior notes
  • Teva Pharmaceutical Industries Limited in connection with its $8.9 billion acquisition of Barr Pharmaceuticals, Inc.
  • Lev Pharmaceuticals, Inc. in connection with its $617.5 million acquisition by ViroPharma Incorporated for a combination of cash, stock and contingent value rights
  • Teva Pharmaceutical Industries Limited in connection with its approximately $360 million acquisition of  Bentley Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Limited in connection with its $400 million acquisition of CoGenesys, Inc.
  • Allied World Assurance Company Holdings, Ltd in its $563.4 million share repurchase from a founding shareholder
  • The underwriters in connection with The Allstate Corporation’s $1 billion hybrid offering of subordinated debentures
  • Marsh Inc. in connection with the creation of MaRI (Marsh Risk Innovations), a first-of-its-kind insurance facility designed to provide additional capacity to the depleted property catastrophe insurance market
  • Teva Pharmaceutical Industries Limited in connection with its $9.9 billion acquisition of Ivax Corporation and its $3.4 billion acquisition of Sicor Inc
  • Teva Pharmaceutical Industries Limited in connection with various registered and Rule 144A convertible debt offerings in excess of $5 billion
  • The underwriters in connection with various debt and hybrid securities offerings by The Allstate Corporation and PartnerRe Ltd. aggregating approximately $4.5 billion
  • Strayer Education, Inc. in connection with public offerings of its common stock
  • Numerous private equity investments and acquisitions for Warburg Pincus & Co. and its portfolio companies
  • RenaissanceRe Holdings Ltd. in connection with various joint ventures and “sidecar” transactions
  • Special Committee of Juniper Financial in connection with a proposed financing from its controlling shareholder and the Special Committee of Hartford Life in connection with its $1.1 billion “going private” transaction
  • Peter J. Solomon Company in its capacity as financial adviser to Lands’ End in connection with its $1.9 billion sale to Sears
  • MidAmerican Energy in its $9 billion “going private” merger

Selected Professional and Business Activities

Jeffrey is a member of the Business Law Section of the American Bar Association. He has spoken on the Sarbanes-Oxley Act and corporate governance issues, MD&A, negotiating merger agreements and other corporate and securities issues for the Practising Law Institute.